El interés en corto de ZyVersa Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de ZyVersa Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

ZyVersa Therapeutics (NASDAQ:ZVSA) Bolsa, Informe de interés en corto

ZyVersa Therapeutics

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics Inc

<p><strong>Texas Instruments Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) reported its third-quarter financial results after Tuesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/10/n41465683/ti-reports-third-quarter-2024-financial-results-and-shareholder-returns">details from the report.&nbsp;</a></p>
<p><strong>The Details:</strong> Texas Instruments reported quarterly earnings of $1.47 per share, which beat the analyst consensus estimate of $1.37. Quarterly revenue of $4.151 billion beat the consensus estimate of $4.12 billion.</p>
<p>&#8220;Industrial continued to decline sequentially, while all other end markets grew. Our cash flow from operations of $6.2 billion for the trailing 12 months again underscored the strength of our business model, the quality of our product portfolio and the benefit of 300mm production. Free cash flow for the same period was $1.5 billion,&#8221; said <strong>Haviv Ilan</strong>, CEO of Texas Instruments.</p>
<p>&#8220;Over the past 12 months we invested $3.7 billion in R&amp;D and SG&amp;A, invested $4.8 billion in capital expenditures and returned $5.2 billion to owners,&#8221; Ilan added.</p>
<p><strong>Read Next: </strong><a href="https://www.benzinga.com/news/24/10/41418987/nuclear-energy-stocks-are-hot-heres-a-list-of-tickers-to-watch"><strong>Nuclear Energy Stocks Are Hot: Here&#8217;s A List Of Tickers To Watch</strong></a></p>
<p><strong>Outlook:</strong> Texas Instruments sees fourth-quarter earnings between $1.07 and $1.29 per share, versus the $1.34 estimate and quarterly revenue in a range of $3.7 billion to $4 billion, versus the $4.07 billion consensus estimate. </p>
<p><strong>TXN Price Action:</strong> According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Texas Instruments shares are seesawing after the close, but at publication on Tuesday were up 0.015% at $194.</p>
<p><strong>Read Also:&nbsp;</strong></p>
<ul>
<li><strong>&nbsp;</strong><a href="https://www.benzinga.com/news/24/10/41415824/lucid-ceo-peter-rawlinson-talks-saudi-investment-elon-musks-political-views-and-taking-business-from"><strong>Lucid CEO Peter Rawlinson Talks Saudi Investment, Elon Musk&#8217;s Political Views And Taking Business From Tesla</strong></a></li>
</ul>
<p><em>Photo: Shutterstock&nbsp;</em></p>


Earnings

News

After-Hours Center

Movers

Tech

Texas Instruments Shares Seesaw After Q3 Results Beat Estimates, Weak Q4 Guidance

<p>The First Bancshares, Inc. ("The First") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBMS#NYSE">FBMS</a>), holding company for The First Bank, (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.thefirstbank.com&amp;esheet=54140569&amp;newsitemid=20241022552905&amp;lan=en-US&amp;anchor=www.thefirstbank.com&amp;index=1&amp;md5=48fd2241736b076ad99d73a53a69831d">www.thefirstbank.com</a>), announced today that the previously announced merger between The First and Renasant Corporation ("Renasant"), pursuant to the Agreement and Plan of Merger, dated as of July 29, 2024, (the "Merger Agreement"), has been approved by its shareholders. Completion of the transaction remains subject to customary closing conditions, including the receipt of required regulatory approvals.</p>


FBMS

The First Bancshares Announces Receipt Of Shareholder Approval For Merger

WIIM

BROS

Dutch Bros shares are trading lower amid sympathy with Starbucks after the company reported Q4 financial results and suspended 2025 guidance.

<p>Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has outperformed the market over the past 10 years by 18.31% on an annualized basis producing an average annual return of 29.7%. Currently, Tesla has a market capitalization of $696.36 billion. </p>
<p><strong>Buying $100 In TSLA:</strong> If an investor had bought $100 of TSLA stock 10 years ago, it would be worth <strong>$1,474.96</strong> today based on a price of $217.98 for TSLA at the time of writing.</p>
<h3>Tesla's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729629259_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

TSLA

$100 Invested In Tesla 10 Years Ago Would Be Worth This Much Today

<p><strong>Kroger will use RFID sensors to enable item-level digital identification for greater inventory accuracy to maximize freshness, reduce waste and optimize associates' time</strong></p>
<p>Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) announced today it will begin working with The Kroger Co. to build a better associate and customer experience through RFID inventory automation technology. This collaboration makes item-level digital identification possible, enabling more frequent and more accurate inventory information to maximize freshness, reduce waste and improve the associate experience.</p>


Avery Dennison Announces It Will Begin Working With The Kroger Co. To Build A Better Associate And Customer Experience Through RFID Inventory Automation Technology

MANH

Manhattan Associates shares are trading lower. The company reported Q3 financial results.

WFRD

Weatherford Q3 Revenue $1.409B; GAAP EPS $2.06 Per Share Vs $1.66 In Q2

<p>PennyMac Financial Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFSI#NYSE">PFSI</a>) reported quarterly earnings of $3.49 per share which beat the analyst consensus estimate of $2.90 by 20.34 percent.</p>


Earnings Beats

Earnings Misses

PFSI

PennyMac Financial Servs Q3 2024 Adj EPS $3.49 Beats $2.90 Estimate

<p>Bank of N.T Butterfield (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTB#NYSE">NTB</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.14 by 1.75 percent.  The company reported quarterly sales of $142.700 million which beat the analyst consensus estimate of $142.472 million by 0.16 percent.  This is a 0.71 percent increase over sales of $141.700 million the same period last year.</p>


Bank of N.T Butterfield Q3 2024 Adj. EPS $1.16 Beats $1.14 Estimate, Sales $142.700M Beat $142.472M Estimate

Biotech

General

ANRO

Alto Neuroscience Announces That The Phase 2b Study Of ALTO-100 In Patients With Major Depressive Disorder Did Not Meet Its Primary Endpoint, Assessed By A Change From Baseline In Montgomery-Åsberg Depression Rating Scale, Compared To Placebo

<p>Argentina has introduced new regulations for the hemp industry through&nbsp;<strong>Resolution 1/2024</strong>, signed by <strong>Ignacio Ferrari</strong>, director of the Regulatory Agency for the Hemp and Medicinal Cannabis Industry (ARICCAME). </p>
<p>These regulations introduce a simplified system that distinguishes between agricultural and industrial activities.</p>
<p>ARICCAME, which oversees hemp and cannabis activities, <a href="https://www.benzinga.com/markets/cannabis/24/09/40926566/argentinas-cannabis-industry-shakeup-will-the-new-government-appointed-comptroller-boost-busines">has been restructured</a> under to resolve operational issues.</p>
<p>The agency&#8217;s new leadership now holds expanded powers to issue licenses and coordinate with other regulatory authorities to ensure compliance with the updated regulations, first <a href="https://elplanteo.com/regulaciones-canamo-licencias-argentina/">reported</a> El Planteo.</p>
<h3 class="wp-block-heading"><strong>Argentina's Hemp Potential In the Global Market</strong></h3>
<p>Argentina is already a key player in global agriculture, known for its vast production of commodities like soybeans, meat and corn.</p>
<p>The country's agricultural prowess positions it as a potential major exporter of hemp, offering products like seeds, fibers and oils at competitive prices.</p>
<p>If Argentina's <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/markets/cannabis/24/08/40418137/industrial-hemps-14b-projected-growth-an-investment-opportunity-too-good-to-miss&amp;ved=2ahUKEwiMotKLpaKJAxUuqpUCHabjC6cQFnoECBMQAQ&amp;usg=AOvVaw0tIRFytMtpZRpfLvkTSE66">hemp industry</a> gains momentum, it could drive down global prices and create significant opportunities in international markets, benefiting industries like textiles and pharmaceuticals.</p>
<p>This development could also provide competition to <a href="https://www.benzinga.com/markets/cannabis/24/09/40715126/expert-economist-slashes-hemp-acreage-forecast-by-82-for-2030-heres-why">U.S. hemp producers</a>, as Argentina&#8217;s scale and efficiency may help meet growing global demand at a lower cost.</p>
<ul>
<li><em><strong>Learn all about Argentina's booming cannabis industry and opportunities ahead at El Planteo's <a href="https://elplanteo.com/eventos/cannab2b/" target="_blank" rel="noreferrer noopener">CannaB2B</a> event in Buenos Aires on November 4. <a href="https://share.hsforms.com/1dzCltrUDRSGMSOTerkComg1npzh?__hstc=99187265.ce2611b4134345745d71884123d3462e.1707500707807.1726678078078.1726684863653.678&amp;__hssc=99187265.1.1726684863653&amp;__hsfp=22530479" target="_blank" rel="noreferrer noopener">Sponsorship opportunities</a> are now open.</strong></em></li>
</ul>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40926566/argentinas-cannabis-industry-shakeup-will-the-new-government-appointed-comptroller-boost-busines">Argentina&#8217;s Cannabis Industry Shakeup: Will The New Government-Appointed Comptroller Boost Business Opportunities?</a></strong></p>
<h3 class="wp-block-heading"><strong>Key Licensing Changes And Fees</strong></h3>
<p>One of the significant updates is the repeal of&nbsp;<strong>Resolution No. 2/2023</strong>, which governed provisional permits for activities involving cannabis. Existing permits will remain valid until their expiration, but new applications must follow the updated framework.</p>
<p>The new resolution outlines two types of licenses for <a href="https://www.benzinga.com/topic/hemp">industrial hemp</a> production:</p>
<ul>
<li><strong>Agricultural License</strong>: Covers cultivation, transportation, and processing of hemp seeds and fiber.
<ul>
<li>0-100 hectares: no cost.</li>
<li>101-500 hectares: $500,000 annually ($<strong>550</strong>)</li>
<li>501-1000 hectares: $1,000,000 annually ($<strong>1100</strong>)</li>
<li>More than 1000 hectares: $2,000,000 annually. ($<strong>2200</strong>)</li>
</ul>
</li>
<li><strong>Industrial License</strong>: Governs commercialization, distribution, import, and export of hemp products, with an annual fee of $1,000,000. ($<strong>1100</strong>)</li>
</ul>
<p><strong>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/10/41371814/guaran-cannabis-lands-in-europe-paraguay-to-export-100-of-its-flower-production">Guaraní Cannabis Lands In Europe: Paraguay To Export 100% Of Its Flower Production</a></strong></p>
<p><em>Cover: Benzinga edit based on&nbsp;Photo by <a href="https://unsplash.com/es/@eirhealth?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash" target="_blank" rel="noreferrer noopener">Eir Health</a>&nbsp;via Unsplash </em><a href="https://unsplash.com/es/fotos/un-gran-grupo-de-plantas-verdes-en-un-campo-KPoxs_DA500?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash" target="_blank" rel="noreferrer noopener"></a><a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" target="_blank" rel="noreferrer noopener"></a></p>


Cannabis

Markets

Hemp Finally Gets Regulated In Argentina: Will It Boom Like The Country's Many Other Ag Products?

TGLS

Tecnoglass shares are trading lower. Sidoti & Co. downgraded the stock from Buy to Neutral and announced a price target of $78.

<p><i>– Treatment with ALTO-100 did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker –</i></p>
<p><i>– ALTO-100 demonstrated a favorable safety and tolerability profile, consistent with previously reported studies –</i></p>
<p><i>– Strong cash position expected to fund Alto's planned operations through multiple near-term milestones across pipeline of independent programs –</i></p>
<p>Alto Neuroscience, Inc. ("Alto") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>), a clinical stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo. The favorable safety and tolerability profile of ALTO-100 was consistent with previously reported studies.</p>


Alto Neuroscience Reports Topline Results From A Phase 2b Trial Evaluating ALTO-100 As A Treatment For Major Depressive Disorder; Says  Treatment With ALTO-100 Did Not Demonstrate Improvement In Depressive Symptoms Compared To Placebo In Patients With A Memory-based Cognitive Biomarker

<p>Financial giants have made a conspicuous bearish move on RTX. Our analysis of options history for RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) revealed 16 unusual trades.</p>
<p>Delving into the details, we found 25% of traders were bullish, while 68% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $217,787, and 10 were calls, valued at $592,142.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $70.0 to $135.0 for RTX over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for RTX options trades today is 1306.5 with a total volume of 43,194.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for RTX's big money trades within a strike price range of $70.0 to $135.0 over the last 30 days.</p>
<h3>RTX Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729629079_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$7.5</td>
<td>$7.45</td>
<td>$7.5</td>
<td>$125.00</td>
<td>$150.0K</td>
<td>1.2K</td>
<td style="text-align: right;">248</td>
</tr>
<tr>
<td>RTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$12.25</td>
<td>$11.75</td>
<td>$11.8</td>
<td>$120.00</td>
<td>$94.4K</td>
<td>161</td>
<td style="text-align: right;">80</td>
</tr>
<tr>
<td>RTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$1.79</td>
<td>$1.5</td>
<td>$1.53</td>
<td>$130.00</td>
<td>$82.1K</td>
<td>5.7K</td>
<td style="text-align: right;">586</td>
</tr>
<tr>
<td>RTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$9.05</td>
<td>$8.85</td>
<td>$8.95</td>
<td>$125.00</td>
<td>$62.6K</td>
<td>8</td>
<td style="text-align: right;">77</td>
</tr>
<tr>
<td>RTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$57.0</td>
<td>$56.6</td>
<td>$56.6</td>
<td>$70.00</td>
<td>$56.6K</td>
<td>281</td>
<td style="text-align: right;">10</td>
</tr>
</tbody>
</table>
</p>
<h3>About RTX</h3>
<p>RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace and to the defense market. The company operates in three segments: Collins Aerospace, a diversified aerospace supplier; Pratt &amp; Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.</p>
<h3>RTX's Current Market Status</h3>
<ul>
<li>With a volume of 5,733,440, the price of RTX is down -0.25% at $125.58. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 0 days.</li>
</ul>
<h3>What The Experts Say On RTX</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $130.5.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Citigroup has decided to maintain their Neutral rating on RTX, which currently sits at a price target of $132.<br />
&#x2A; An analyst from Deutsche Bank upgraded its action to Hold with a price target of $129. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest RTX options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

What the Options Market Tells Us About RTX

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Etsy</strong>.</p>
<p>Looking at options history for Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) we detected 20 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with bullish expectations and 40% with bearish.</p>
<p>From the overall spotted trades, 14 are puts, for a total amount of $1,900,177 and 6, calls, for a total amount of $415,310.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $30.0 to $85.0 for Etsy over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Etsy stands at 1506.79, with a total volume reaching 2,729.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Etsy, situated within the strike price corridor from $30.0 to $85.0, throughout the last 30 days.</p>
<h3>Etsy Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729629073_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ETSY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$21.5</td>
<td>$21.15</td>
<td>$21.15</td>
<td>$70.00</td>
<td>$926.3K</td>
<td>162</td>
<td style="text-align: right;">532</td>
</tr>
<tr>
<td>ETSY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$10.15</td>
<td>$9.75</td>
<td>$9.9</td>
<td>$50.00</td>
<td>$239.5K</td>
<td>1.0K</td>
<td style="text-align: right;">265</td>
</tr>
<tr>
<td>ETSY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$9.9</td>
<td>$9.85</td>
<td>$9.9</td>
<td>$50.00</td>
<td>$228.6K</td>
<td>22</td>
<td style="text-align: right;">8</td>
</tr>
<tr>
<td>ETSY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$21.2</td>
<td>$21.1</td>
<td>$21.1</td>
<td>$70.00</td>
<td>$170.9K</td>
<td>162</td>
<td style="text-align: right;">81</td>
</tr>
<tr>
<td>ETSY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$31.75</td>
<td>$30.6</td>
<td>$31.65</td>
<td>$80.00</td>
<td>$110.7K</td>
<td>105</td>
<td style="text-align: right;">65</td>
</tr>
</tbody>
</table>
</p>
<h3>About Etsy</h3>
<p>Etsy operates a top-10 e-commerce marketplace operator in the us and the UK, with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.2 billion in 2023 consolidated gross merchandise volume, Etsy has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2023, the firm connected more than 96 million buyers and 9 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), and Depop (clothing resale).</p>
<h3>Current Position of Etsy</h3>
<ul>
<li>Currently trading with a volume of 2,938,605, the ETSY's price is down by -4.71%, now at $49.33. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 8 days.</li>
</ul>
<h3>What Analysts Are Saying About Etsy</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $55.2.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from Truist Securities lowers its rating to Buy with a new price target of $76.<br />
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Etsy, targeting a price of $58.<br />
&#x2A; An analyst from Goldman Sachs has revised its rating downward to Sell, adjusting the price target to $45.<br />
&#x2A; An analyst from Wells Fargo persists with their Underweight rating on Etsy, maintaining a target price of $47.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $50. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Etsy with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


ETSY

Etsy Options Trading: A Deep Dive into Market Sentiment

<p>Deep-pocketed investors have adopted a bullish approach towards Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MU usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 82 extraordinary options activities for Micron Technology. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 50% leaning bullish and 45% bearish. Among these notable options, 30 are puts, totaling $3,427,719, and 52 are calls, amounting to $2,969,808.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $60.0 to $150.0 for Micron Technology over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Micron Technology's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Micron Technology's substantial trades, within a strike price spectrum from $60.0 to $150.0 over the preceding 30 days.</p>
<h3>Micron Technology Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729629068_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$26.35</td>
<td>$26.25</td>
<td>$26.35</td>
<td>$130.00</td>
<td>$524.3K</td>
<td>564</td>
<td style="text-align: right;">400</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$26.15</td>
<td>$25.95</td>
<td>$26.15</td>
<td>$130.00</td>
<td>$523.0K</td>
<td>564</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$11.3</td>
<td>$11.25</td>
<td>$11.3</td>
<td>$92.50</td>
<td>$223.7K</td>
<td>411</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$21.55</td>
<td>$21.45</td>
<td>$21.45</td>
<td>$120.00</td>
<td>$214.5K</td>
<td>3.0K</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$21.85</td>
<td>$21.45</td>
<td>$21.45</td>
<td>$120.00</td>
<td>$214.5K</td>
<td>3.0K</td>
<td style="text-align: right;">100</td>
</tr>
</tbody>
</table>
</p>
<h3>About Micron Technology</h3>
<p>Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.</p>
<p>In light of the recent options history for Micron Technology, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Micron Technology Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 12,654,811, the MU's price is down by -1.27%, now at $107.69. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 57 days.</li>
</ul>
<h3>Professional Analyst Ratings for Micron Technology</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $132.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Outperform rating on Micron Technology with a target price of $150.<br />
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Micron Technology, targeting a price of $114.<br />
&#x2A; Consistent in their evaluation, an analyst from Raymond James keeps a Outperform rating on Micron Technology with a target price of $140.<br />
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Micron Technology, which currently sits at a price target of $125.<br />
&#x2A; Maintaining their stance, an analyst from TD Cowen continues to hold a Buy rating for Micron Technology, targeting a price of $135. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Micron Technology, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


This Is What Whales Are Betting On Micron Technology

<h3>Gainers</h3>
<ul>
<li><strong>Protagenic Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock rose 21.4% to $0.78 during Tuesday's after-market session. The market value of their outstanding shares is at $3.4 million. </li>
<li><strong>Talphera</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) shares increased by 11.7% to $1.05. The market value of their outstanding shares is at $17.8 million. </li>
<li><strong>Context Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) shares rose 8.49% to $2.17. The market value of their outstanding shares is at $162.7 million. </li>
<li><strong>Fortrea Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) shares rose 6.68% to $18.99. The company's market cap stands at $1.7 billion. </li>
<li><strong>Genelux</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) stock rose 6.15% to $2.76. The market value of their outstanding shares is at $95.3 million. </li>
<li><strong>ENDRA Life Sciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock rose 5.26% to $0.44. The company's market cap stands at $7.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>TELA Bio</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) shares declined by 15.7% to $2.1 during Tuesday's after-market session. The market value of their outstanding shares is at $51.8 million. </li>
<li><strong>Ensysce Biosciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares declined by 11.45% to $0.48. The company's market cap stands at $6.6 million. </li>
<li><strong>Genprex</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock decreased by 10.59% to $3.21. The market value of their outstanding shares is at $8.3 million. </li>
<li><strong>Allakos</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) stock declined by 6.72% to $1.25. The market value of their outstanding shares is at $111.0 million. </li>
<li><strong>Sensei Biotherapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) shares declined by 6.71% to $0.58. The company's market cap stands at $14.5 million. </li>
<li><strong>TuHURA Biosciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) stock decreased by 6.67% to $4.9. The market value of their outstanding shares is at $205.8 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ALLK

CNTX

ENSC

FTRE

GNLX

GNPX

HURA

NDRA

PTIX

SNSE

TELA

TLPH

12 Health Care Stocks Moving In Tuesday's After-Market Session

GATX

GATX shares are trading higher after the company reported better-than-expected Q3 financial results.

<h3>Gainers</h3>
<ul>
<li><strong>Farmmi</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAMI#NASDAQ">FAMI</a>) stock moved upwards by 147.6% to $0.78 during Tuesday's after-market session. The market value of their outstanding shares is at $8.3 million. </li>
<li><strong>Australian Oilseeds Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOT#NASDAQ">COOT</a>) stock increased by 28.04% to $1.05. The market value of their outstanding shares is at $24.3 million. </li>
<li><strong>Blue Star Foods</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSFC#NASDAQ">BSFC</a>) shares moved upwards by 4.01% to $0.62. The company's market cap stands at $1.5 million. </li>
<li><strong>Reborn Coffee</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REBN#NASDAQ">REBN</a>) shares rose 3.99% to $2.34. The market value of their outstanding shares is at $9.3 million. </li>
<li><strong>Olaplex Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>) stock moved upwards by 3.82% to $2.11. The company's market cap stands at $1.3 billion. </li>
<li><strong>Flora Growth</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ">FLGC</a>) stock increased by 3.22% to $1.6. The market value of their outstanding shares is at $21.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Chanson International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHSN#NASDAQ">CHSN</a>) shares decreased by 8.2% to $11.0 during Tuesday's after-market session. The market value of their outstanding shares is at $235.4 million. </li>
<li><strong>Tyson Foods</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) shares declined by 4.76% to $56.09. The market value of their outstanding shares is at $19.9 billion. </li>
<li><strong>Maison Solutions</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSS#NASDAQ">MSS</a>) stock declined by 4.54% to $1.05. The company's market cap stands at $20.6 million. </li>
<li><strong>Real Good Food Co</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGF#NASDAQ">RGF</a>) shares fell 4.38% to $0.35. The market value of their outstanding shares is at $6.8 million. </li>
<li><strong>Top Wealth Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) stock declined by 3.36% to $9.5. The company's market cap stands at $532.0 million. </li>
<li><strong>Upexi</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) shares decreased by 2.68% to $4.0. The market value of their outstanding shares is at $4.1 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-consumer-defensive-stocks/" title="www.benzinga.com/money/best-consumer-defensive-stocks/">www.benzinga.com/money/best-consumer-defensive-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BSFC

CHSN

COOT

FAMI

FLGC

Merrill Lynch & Strategic Return Notes for Select 10 Index

OLPX

REBN

UPXI

12 Consumer Staples Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Vicor</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VICR#NASDAQ">VICR</a>) shares rose 9.8% to $47.69 during Tuesday's after-market session. The company's market cap stands at $2.1 billion. The company's, Q3 earnings came out today. </li>
<li><strong>Turbo Energy</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TURB#NASDAQ">TURB</a>) stock increased by 5.52% to $1.72. The company's market cap stands at $18.9 million. </li>
<li><strong>FTC Solar</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) shares rose 4.99% to $0.66. The company's market cap stands at $84.8 million. </li>
<li><strong>Hyperscale Data</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) stock moved upwards by 3.51% to $0.23. The market value of their outstanding shares is at $9.0 million. </li>
<li><strong>Nauticus Robotics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) shares moved upwards by 3.12% to $1.39. The company's market cap stands at $6.4 million. </li>
<li><strong>Intelligent Living</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) shares moved upwards by 2.88% to $1.0. The company's market cap stands at $18.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Graphex Gr</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GRFX#AMEX">GRFX</a>) stock fell 12.2% to $0.21 during Tuesday's after-market session. The company's market cap stands at $10.6 million. </li>
<li><strong>noco-noco</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNC#NASDAQ">NCNC</a>) shares declined by 5.58% to $0.13. The company's market cap stands at $25.5 million. </li>
<li><strong>New Horizon Aircraft</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) stock decreased by 4.33% to $0.33. The market value of their outstanding shares is at $7.9 million. </li>
<li><strong>JE Cleantech Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCSE#NASDAQ">JCSE</a>) stock fell 3.98% to $1.45. The market value of their outstanding shares is at $7.2 million. </li>
<li><strong>Staffing 360 Solutions</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) stock declined by 3.51% to $1.93. The market value of their outstanding shares is at $1.7 million. </li>
<li><strong>Robert Half</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHI#NYSE">RHI</a>) shares fell 3.51% to $63.4. The market value of their outstanding shares is at $6.5 billion. The company's, Q3 earnings came out today.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FTCI

GPUS

GRFX

HOVR

ILAG

JCSE

KITT

NCNC

STAF

TURB

VICR

12 Industrials Stocks Moving In Tuesday's After-Market Session

PHG, IBRX and MESO are among premarket gainers

ImmunityBio, Aquestive Therapeutics, Clever Leaves Holdings among healthcare movers

CRVS, CTMX and NRXP are among premarket  gainers

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>ZyVersa Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/zvsa-stock-quote/"><strong>ZVSA</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>ZyVersa Therapeutics reported earnings per share of -$4.53. This was below the analyst estimate for EPS of -$3.70.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/zvsa-stock-earnings-zyversa-therapeutics-for-q1-of-2024/">ZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024

ZyVersa Therapeutics GAAP EPS of -$4.53 misses by $0.78

ZyVersa Therapeutics GAAP EPS of -$3.31 beats by $0.44

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>ZyVersa Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/zvsa-stock-quote/"><strong>ZVSA</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>ZyVersa Therapeutics reported earnings per share of -$3.31. This was above the analyst estimate for EPS of -$3.75.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/zvsa-stock-earnings-zyversa-therapeutics-for-q2-of-2024/">ZVSA Stock Earnings: ZyVersa Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ZVSA Stock Earnings: ZyVersa Therapeutics Beats EPS for Q2 2024

ZyVersa Therapeutics files for mixed shelf offering

Warning: ZVSA is at high risk of performing badly

ABVC

ADXN

AGBA

AQST

ATXI

BENF

CJJD

CLVR

DCPH

HOLO

HSAI

IBRX

ICLK

IMTE

INCR

MESO

NITO

NIVF

NUVO

OPTN

SLNO

SWIN

ZVSA

Screenshot 2024-03-29 at 1.05.42 AM

CEO Of This Leading Biotech Speaks To The Critical Nature Inflammation Plays In The Body

Press Releases

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024

Health Care

ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model

ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100

ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults

ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months

Analyst Ratings

ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases

Comments

ZyVersa Therapeutics

Interés en corto

ZyVersa Therapeutics (NASDAQ:ZVSA) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL